Literature DB >> 20812307

Phenotype of five cases of prenatally diagnosed campomelic dysplasia harboring novel mutations of the SOX9 gene.

B Gentilin1, F Forzano, M F Bedeschi, T Rizzuti, F Faravelli, C Izzi, M Lituania, C Rodriguez-Perez, M P Bondioni, G Savoldi, E Grosso, G Botta, E Viora, A M Baffico, F Lalatta.   

Abstract

OBJECTIVES: Campomelic dysplasia is a rare congenital skeletal disorder characterized by bowing of the long bones and a variety of other skeletal and extraskeletal defects, many of which can now be identified prenatally using advanced ultrasound equipment. The disorder is caused by mutations in SRY-box 9 (SOX9), a gene that is abundantly expressed in chondrocytes as well as in other tissues. However, the correlation between genotype and phenotype is still unclear. We report five cases of prenatally detected campomelic dysplasia in which the diagnosis was confirmed by molecular analysis.
METHODS: Ultrasound examinations were performed between 12 and 32 weeks. Standard fetal biometric measurements were obtained. Fetal sex was determined sonographically and confirmed by chromosomal analysis. Genomic DNA was obtained in four cases before termination of pregnancy from chorionic villi or amniocytes and in one case postnatally from peripheral blood.
RESULTS: Skeletal dysplasia, most often limb shortening and bowed femora, was observed in one case in the first trimester, in three cases in the second trimester and in one case, presenting late for antenatal care, in the third trimester. Four of the pregnancies were terminated and one was carried to term. Postmortem/postnatal physical and radiographic examinations confirmed the presence of anomalies characteristic of campomelic dysplasia. A de novo mutation in the SOX9 gene was detected in all four cases that underwent termination. The father of the proband in the case that went to term was a carrier of a somatic mosaic mutation without clinical or radiographic signs of campomelic dysplasia.
CONCLUSIONS: It is likely that the integrated expertise of ultrasonographers, obstetricians, pediatricians and clinical geneticists will markedly improve the likelihood of accurate prenatal clinical diagnoses of campomelic dysplasia. This will, in turn, encourage more specific molecular testing and facilitate comprehensive genetic counseling. (c) 2010 ISUOG. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20812307     DOI: 10.1002/uog.7761

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  5 in total

Review 1.  Mechanisms of bone development and repair.

Authors:  Ankit Salhotra; Harsh N Shah; Benjamin Levi; Michael T Longaker
Journal:  Nat Rev Mol Cell Biol       Date:  2020-09-08       Impact factor: 94.444

2.  Dominant-negative SOX9 mutations in campomelic dysplasia.

Authors:  Fabiana Csukasi; Ivan Duran; Wenjuan Zhang; Jorge H Martin; Maya Barad; Michael Bamshad; Mary Ann Weis; David Eyre; Deborah Krakow; Daniel H Cohn
Journal:  Hum Mutat       Date:  2019-08-26       Impact factor: 4.878

3.  Clinical and molecular characterization of a Brazilian cohort of campomelic dysplasia patients, and identification of seven new SOX9 mutations.

Authors:  Eduardo P Mattos; Maria Teresa V Sanseverino; José Antônio A Magalhães; Júlio César L Leite; Temis Maria Félix; Luiz Alberto Todeschini; Denise P Cavalcanti; Lavinia Schüler-Faccini
Journal:  Genet Mol Biol       Date:  2014-03-17       Impact factor: 1.771

4.  SOX9-COL9A3-dependent regulation of choroid plexus epithelial polarity governs blood-cerebrospinal fluid barrier integrity.

Authors:  Keng Ioi Vong; Tsz Ching Ma; Baiying Li; Thomas Chun Ning Leung; Wenyan Nong; Sai Ming Ngai; Jerome Ho Lam Hui; Liwen Jiang; Kin Ming Kwan
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

Review 5.  Diverse Regulation but Conserved Function: SOX9 in Vertebrate Sex Determination.

Authors:  Brittany Vining; Zhenhua Ming; Stefan Bagheri-Fam; Vincent Harley
Journal:  Genes (Basel)       Date:  2021-03-26       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.